SynthesisJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025
Efficacy and safety of Compound E'jiao Jiang for treating leukopenia based: a systematic review and Meta-analysis.
Synthesis in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo systematically assess the safety and effectiveness of Compound E'jiao Jiang (, CEJ) for treating leukopenia.
methodsFour English and four Chinese databases were searched for randomized controlled trials (RCTs) on CEJ for treating leukopenia up to July 1, 2024. Two researchers independently screened the studies and extracted necessary data. Methodological quality and risk of bias were assessed using the Cochrane risk-of-bias tool. Articles eligible for Meta-analysis were analyzed using RevMan.
resultsA total of 28 RCTs involving 2041 participants were included, with 1034 in the experimental group and 1007 in the control group. The Meta-analysis showed a significant effect of CEJ in treating leukopenia caused by tumor and immune diseases (three RCTs) [risk ratio (
conclusionCEJ alone or in combination with Western Medicine for treating leukopenia caused by tumor and immune diseases improved WBC counts, clinical efficacy, and quality of life. It also reduced bone marrow toxicity-induced leukopenia, enhanced the efficacy of chemotherapy while reducing its toxicity, and alleviated symptoms. No significant adverse events were reported in the RCTs, indicating favorable efficacy and safety. The Grading of Recommendations Assessment, Development and Evaluation assessment indicated a low level of evidence for CEJ in improving leukocyte elevation efficacy, KPS levels, and myelosuppressive toxicity. Therefore, large-scale, high-quality, rigorous multicenter double-blind controlled trials are recommended to strengthen the evidence level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.